SXTC
China Sxt Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CN
$0.08
+24.00%Year over year
Reported trailing growth
- Revenue
- -38.4%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- -96.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -18.4%
- EBITDA
- —
- EBIT
- —
- Net income
- -87.8%
- EPS
- -11.6%
- Free cash flow
- -71.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026